Program Goals. Program Goals Introduction Causes of Hypoparathyroidism.

Slides:



Advertisements
Similar presentations
Hypoparathyroidism: the hormone replacement therapy is close
Advertisements

429 pharmaceutical care Plan Refa’a AlAjmi. Goal of therpay A goal of therapy is the desired response or endpoint that you and your patient want to achieve.
Dr Annie NK Chiu United Christian Hospital Joint Hospital Surgical Grand Round 20 th Apr 2013.
Osteoporosis Research Center The Burden of Osteoporosis Estimates are that by the year 2020, one in two Americans will have or be at high risk for osteoporosis.
HYPOCALCEMIA MBBS 2011 BATCH 06/08/14. CALCIUM Total body calcium content- 1-2 kg 99% of it is within the bone in the form of hydroxyapatite It is present.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 75 Drugs Affecting Calcium Levels and Bone Mineralization.
Chronic Kidney Disease-Mineral and Bone Disorder
NYU Medical Grand Rounds Clinical Vignette Deepa Rani Nandiwada, M.D. PGY 2 November 1, 2011 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
OSTEOPOROSIS CHOICE Decision Aid
Milk-Alkali Syndrome and Evaluation of Hypercalcemia Morning Report 8/18/2009 TJ O’Neill.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
Introduction to prosthodontic By DR. mohammed almuhaiza.
X RAYS OF METABOLIC BONE DISEASES
The significance of early detection, diagnosis and treatment of asymptomatic primary hyperparathyroidism in primary health care Dr Aleksandra Ješić Dr.
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Surgical Treatment of Hyperparathyroidism in Patients.
US Burden of Disease and Injury Study, 1996
Endocrine Disorders Parathyroid Gland
Estimation of Phosphate
Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase.
Multimodal Management of Opioid-Induced Constipation
Drugs Affecting Calcium Levels and Bone Mineralization
Pain Management Doctor San Antonio | Spine Care in San Antonio Texas
Introduction CKD-MBD. Introduction CKD-MBD Regulation of PTH Secretion.
D2d participating clinical sites
Chronic kidney disease and pre-dialysis
Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018
Chronic Hepatitis C Virus Infection
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Starting Strong: Initial Evaluation of the Patient With HCV
Gout Management.
Optimizing Outcomes in Short Bowel Syndrome With IF
Goals of Therapy for Patients With UC
Thrombosis, Cancer, and NOACs
Bone metabolism and disease in chronic kidney disease
Ask the Onychomycosis Expert, Part 2
Ask the Onychomycosis Expert, Part 1
The Latest Data on Oral Prostacyclin Therapy in PAH
What Is New in HCM?.
Complicated Cases in Ulcerative Colitis
Addressing Iron Deficiency in Chronic HF
Furosemide-Induced Severe Hypocalcemia in Latent Hypoparathyroidism
American Journal of Kidney Diseases 
Chronic Idiopathic Urticaria
A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.
Guidelines American Journal of Kidney Diseases
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
Hyperhidrosis Is Burdensome!
Program Goals. Program Goals Introduction Causes of Hypoparathyroidism.
Primary Biliary Cholangitis
The Evolving Treatment Landscape in Atopic Dermatitis
Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.
5 Things You Need to Know About Hypoparathyroidism
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Chapter 3: Management of progression and complications of CKD
LALD Introduction Patient Case Presentation.
Severe Constipation Clinical Gastroenterology and Hepatology
A Multidisciplinary Perspective on the Management of Hypoparathyroidism.
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
AMD Therapy: Where Are We Now and Where Are We Going?
At the Crossroads of Coagulation
Omega-3s vs Pure EPA in Clinical Practice
PAH Pathways: What Do the Data Tell Us?”
Osteoporosis: Definition
Clinical Comparisons in CTEPH
Multimodality imaging of aortic stenosis.
Volume 63, Issue 2, Pages (February 2003)
The Building Blocks of Homocystinuria and Homocysteinemia Management
Treatment Advances for RA
Navigating the Journey
The Power of As-Treated Analyses
Presentation transcript:

Program Goals

Introduction

Causes of Hypoparathyroidism

Clinical Manifestations of Hypoparathyroidism

Patient Case 1

Postsurgical Hypoparathyroidism

Diagnostic Workup Initial Laboratory Evaluation

Goals of Treatment

Patient Case 1 Treatment Plan

Chronic Treatment With Oral Calcium and Vitamin D Supplementation

Hydrochlorothiazide for the Management of Hypercalciuria

Patient Case 1 Follow-Up

Burden of Disease and Treatment

REPLACE Achievement of Primary Endpoint

PTH(1-84) Indication and Safety

PARADOX Study Quality of Life in Hypoparathyroidism

PTH(1-34) Teriparatide*